Drug Profile
ZPL 5212372
Alternative Names: PF-05212372; PF-5212372; PLA-950; ZPL-521; ZPL-5212372Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator
- Developer Pfizer; Ziarco
- Class Antiasthmatics
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Psoriasis
- Discontinued Asthma
Most Recent Events
- 08 Sep 2021 No development reported - Phase-I/II for Atopic dermatitis in United Kingdom (Topical)
- 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Psoriasis(In volunteers) in United Kingdom (Topical)
- 01 Mar 2017 Ziarco completes a phase I/II trial in Atopic dermatitis in United Kingdom (NCT02795832)